Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron : An updated meta-analysis
© 2024 Belgian Health Care Knowledge Centre. Journal of Medical Virology published by Wiley Periodicals LLC..
Nirmatrelvir-ritonavir (NR) was approved to treat SARS-CoV-2 positive outpatients at high risk of progression to severe disease, based on a randomized trial in unvaccinated patients. Effectiveness in vaccinated patients and against Omicron has not yet been confirmed by clinical trial data, but a recent meta-analysis suggested good real-world effectiveness based on 12 studies. We updated this meta-analysis by searching Medline and Embase databases for studies assessing effectiveness of NR on mortality, hospitalization, composite outcome of hospitalization and/or death, and progression to severe disease, published between October 1, 2022 and May 22, 2023. Random effects meta-analysis and subgroup analysis for vaccinated patients was performed. A total of 32 studies were included in the meta-analysis. Pooled RR for the effect of NR on mortality, hospitalization, hospitalization and/or mortality, and progression to severe disease were 0.36 (95% confidence interval [CI]: 0.25-0.52), 0.43 (CI: 0.37-0.51), 0.52 (CI: 0.45-0.61) and 0.54 (CI: 0.41-0.73), respectively. A subgroup analysis on vaccinated patients indicated lower effectiveness of NR on mortality (RR: 0.55, CI: 0.45-0.68), but similar effectiveness for hospitalization, hospitalization and/or mortality, or progression to severe disease (RR: 0.52, 0.58, and 0.66, respectively). This updated meta-analysis robustly confirms the protective effects of NR on severe COVID-19 outcomes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
---|---|
Enthalten in: |
Journal of medical virology - 96(2024), 2 vom: 20. Feb., Seite e29434 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ombelet, Sien [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 22.02.2024 Date Revised 22.02.2024 published: Print Citation Status MEDLINE |
---|
doi: |
10.1002/jmv.29434 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368669998 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM368669998 | ||
003 | DE-627 | ||
005 | 20240222232729.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240222s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/jmv.29434 |2 doi | |
028 | 5 | 2 | |a pubmed24n1302.xml |
035 | |a (DE-627)NLM368669998 | ||
035 | |a (NLM)38376947 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ombelet, Sien |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19 in the era of vaccination and Omicron |b An updated meta-analysis |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.02.2024 | ||
500 | |a Date Revised 22.02.2024 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 Belgian Health Care Knowledge Centre. Journal of Medical Virology published by Wiley Periodicals LLC. | ||
520 | |a Nirmatrelvir-ritonavir (NR) was approved to treat SARS-CoV-2 positive outpatients at high risk of progression to severe disease, based on a randomized trial in unvaccinated patients. Effectiveness in vaccinated patients and against Omicron has not yet been confirmed by clinical trial data, but a recent meta-analysis suggested good real-world effectiveness based on 12 studies. We updated this meta-analysis by searching Medline and Embase databases for studies assessing effectiveness of NR on mortality, hospitalization, composite outcome of hospitalization and/or death, and progression to severe disease, published between October 1, 2022 and May 22, 2023. Random effects meta-analysis and subgroup analysis for vaccinated patients was performed. A total of 32 studies were included in the meta-analysis. Pooled RR for the effect of NR on mortality, hospitalization, hospitalization and/or mortality, and progression to severe disease were 0.36 (95% confidence interval [CI]: 0.25-0.52), 0.43 (CI: 0.37-0.51), 0.52 (CI: 0.45-0.61) and 0.54 (CI: 0.41-0.73), respectively. A subgroup analysis on vaccinated patients indicated lower effectiveness of NR on mortality (RR: 0.55, CI: 0.45-0.68), but similar effectiveness for hospitalization, hospitalization and/or mortality, or progression to severe disease (RR: 0.52, 0.58, and 0.66, respectively). This updated meta-analysis robustly confirms the protective effects of NR on severe COVID-19 outcomes | ||
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Paxlovid | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a meta-analysis | |
650 | 4 | |a nirmatrelvir-ritonavir | |
650 | 4 | |a systematic review | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
650 | 7 | |a nirmatrelvir |2 NLM | |
650 | 7 | |a 7R9A5P7H32 |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Lactams |2 NLM | |
650 | 7 | |a Leucine |2 NLM | |
650 | 7 | |a GMW67QNF9C |2 NLM | |
650 | 7 | |a Nitriles |2 NLM | |
650 | 7 | |a Proline |2 NLM | |
650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
700 | 1 | |a Castanares-Zapatero, Diego |e verfasserin |4 aut | |
700 | 1 | |a Desimpel, Fabian |e verfasserin |4 aut | |
700 | 1 | |a Hulstaert, Frank |e verfasserin |4 aut | |
700 | 1 | |a Stordeur, Sabine |e verfasserin |4 aut | |
700 | 1 | |a Roberfroid, Dominique |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of medical virology |d 1990 |g 96(2024), 2 vom: 20. Feb., Seite e29434 |w (DE-627)NLM000285676 |x 1096-9071 |7 nnns |
773 | 1 | 8 | |g volume:96 |g year:2024 |g number:2 |g day:20 |g month:02 |g pages:e29434 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/jmv.29434 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 96 |j 2024 |e 2 |b 20 |c 02 |h e29434 |